Despite fewer deals getting done, big money – often at the early stage – drove the total transaction value higher. In all, more 4,000 deals were announced with a potential value of $428B. It was another busy year for biopharma dealmaking!
In the Cortellis 2018 Deals & Portfolio Review, our analysts dig into the strategies behind last year’s biggest deals and key portfolio decisions, with a focus on key companies, therapeutic areas and regions.
Key topics and trends highlighted in the report, include:
Do you have the insights you need to be a player in this year’s dealmaking?
Download the report today!